organization · Reporting owner
WSLS OFFSHORE INVESTMENTS, SLP
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Attovia Therapeutics, Inc.
Report date August 05, 2026 · Filed August 28, 2026 · Amendment
Jointly reported with GOLDMAN SACHS GROUP INC, GOLDMAN SACHS & CO. LLC, GOLDMAN SACHS ASSET MANAGEMENT, L.P., Broad Street Principal Investments, L.L.C., West Street Life Sciences I, L.P., WSLS EMP OFFSHORE INVESTMENTS, L.P., WSLS EMP ONSHORE INVESTMENTS, L.P.
Section 16 reporting ended · disclosed 2026-08-28. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 85,000 |
Reported balance
After 2026-08-05 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-08-05 · Purchase · Acquired 85,000 · Balance 85,000 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 84,012 |
Reported balance
After 2026-08-05 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2026-08-05 · Sale · Disposed 988 · Balance 84,012 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 83,565 |
Reported balance
After 2026-08-05 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2026-08-05 · Sale · Disposed 447 · Balance 83,565 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 82,233 |
Reported balance
After 2026-08-05 transaction · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · 2026-08-05 · Sale · Disposed 1,332 · Balance 82,233 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 82,033 |
Reported balance
After 2026-08-05 transaction · row 5
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 5 · 2026-08-05 · Sale · Disposed 200 · Balance 82,033 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 80,477 |
Reported balance
After 2026-08-05 transaction · row 6
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 6 · 2026-08-05 · Sale · Disposed 1,556 · Balance 80,477 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 77,075 |
Reported balance
After 2026-08-05 transaction · row 7
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 7 · 2026-08-05 · Sale · Disposed 3,402 · Balance 77,075 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 76,875 |
Reported balance
After 2026-08-05 transaction · row 8
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 8 · 2026-08-05 · Sale · Disposed 200 · Balance 76,875 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 76,395 |
Reported balance
After 2026-08-05 transaction · row 9
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 9 · 2026-08-05 · Sale · Disposed 480 · Balance 76,395 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 76,295 |
Reported balance
After 2026-08-05 transaction · row 10
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 10 · 2026-08-05 · Sale · Disposed 100 · Balance 76,295 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 75,542 |
Reported balance
After 2026-08-05 transaction · row 11
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 11 · 2026-08-05 · Sale · Disposed 753 · Balance 75,542 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 74,870 |
Reported balance
After 2026-08-05 transaction · row 12
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 12 · 2026-08-05 · Sale · Disposed 672 · Balance 74,870 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 67,900 |
Reported balance
After 2026-08-05 transaction · row 13
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 13 · 2026-08-05 · Sale · Disposed 6,970 · Balance 67,900 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 67,500 |
Reported balance
After 2026-08-05 transaction · row 14
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 14 · 2026-08-05 · Sale · Disposed 400 · Balance 67,500 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 66,320 |
Reported balance
After 2026-08-05 transaction · row 15
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 15 · 2026-08-05 · Sale · Disposed 1,180 · Balance 66,320 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 65,280 |
Reported balance
After 2026-08-05 transaction · row 16
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 16 · 2026-08-05 · Sale · Disposed 1,040 · Balance 65,280 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 64,980 |
Reported balance
After 2026-08-05 transaction · row 17
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 17 · 2026-08-05 · Sale · Disposed 300 · Balance 64,980 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 64,537 |
Reported balance
After 2026-08-05 transaction · row 18
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 18 · 2026-08-05 · Sale · Disposed 443 · Balance 64,537 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 64,337 |
Reported balance
After 2026-08-05 transaction · row 19
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 19 · 2026-08-05 · Sale · Disposed 200 · Balance 64,337 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 63,637 |
Reported balance
After 2026-08-05 transaction · row 20
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 20 · 2026-08-05 · Sale · Disposed 700 · Balance 63,637 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 62,474 |
Reported balance
After 2026-08-05 transaction · row 21
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 21 · 2026-08-05 · Sale · Disposed 1,163 · Balance 62,474 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 62,374 |
Reported balance
After 2026-08-05 transaction · row 22
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 22 · 2026-08-05 · Sale · Disposed 100 · Balance 62,374 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 55,611 |
Reported balance
After 2026-08-05 transaction · row 23
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 23 · 2026-08-05 · Sale · Disposed 6,763 · Balance 55,611 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 0 |
Reported balance
After 2026-08-05 transaction · row 24
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 24 · 2026-08-05 · Sale · Disposed 76,418 · Balance 0 F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 2,042,134 |
Reported balance
After 2026-08-06 transaction · row 25
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 25 · 2026-08-06 · Conversion · Acquired 1,957,134 · Balance 2,042,134 F4: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F5: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F6: This statement is being filed by Goldman Sachs Group, Inc. ("GS Group"), GS&Co, Goldman Sachs Asset Management, L.P. ("GSAM LP"), Broad Street Principal Investments L.L.C. ("BSPI"), which directly holds 96,190 shares of common stock purchased in the IPO and 468,565 shares of common stock converted from 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock, WSLS Offshore Investments, SLP ("WSLS Offshore"), which directly holds 131,283 shares of common stock purchased in the IPO and 639,518 shares of common stock converted from 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock, West Street Life Sciences I, L.P. ("WSLS I"), which directly holds 137,708 shares of common stock purchased in the IPO and 670,812 shares of common stock converted from 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock,... (continued in footnote 7) F7: (continued from footnote 6)...WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore"), which directly holds 36,927 shares of common stock purchased in the IPO and 179,879 shares of common stock converted from 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore"), which directly holds 97,892 shares of common stock purchased in the IPO and 476,858 shares of common stock converted from 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock. GS&Co is a direct subsidiary of GS Group and is the manager of BSPI. WSLS Offshore, WSLS I, WSLS Emp Offshore, and WSLS Emp Onshore are investment vehicles managed by GSAM LP, an indirect subsidiary of GS Group. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 2,520,632 |
Reported balance
After 2026-08-06 transaction · row 26
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 26 · 2026-08-06 · Conversion · Acquired 478,498 · Balance 2,520,632 F4: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F5: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F6: This statement is being filed by Goldman Sachs Group, Inc. ("GS Group"), GS&Co, Goldman Sachs Asset Management, L.P. ("GSAM LP"), Broad Street Principal Investments L.L.C. ("BSPI"), which directly holds 96,190 shares of common stock purchased in the IPO and 468,565 shares of common stock converted from 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock, WSLS Offshore Investments, SLP ("WSLS Offshore"), which directly holds 131,283 shares of common stock purchased in the IPO and 639,518 shares of common stock converted from 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock, West Street Life Sciences I, L.P. ("WSLS I"), which directly holds 137,708 shares of common stock purchased in the IPO and 670,812 shares of common stock converted from 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock,... (continued in footnote 7) F7: (continued from footnote 6)...WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore"), which directly holds 36,927 shares of common stock purchased in the IPO and 179,879 shares of common stock converted from 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore"), which directly holds 97,892 shares of common stock purchased in the IPO and 476,858 shares of common stock converted from 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock. GS&Co is a direct subsidiary of GS Group and is the manager of BSPI. WSLS Offshore, WSLS I, WSLS Emp Offshore, and WSLS Emp Onshore are investment vehicles managed by GSAM LP, an indirect subsidiary of GS Group. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 3,020,632 |
Reported balance
After 2026-08-06 transaction · row 27
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 27 · 2026-08-06 · Purchase · Acquired 500,000 · Balance 3,020,632 F4: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2026-08-06 transaction · row 28
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 28 · 2026-08-06 · Conversion · Disposed 18,181,830 · Balance 0 F4: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F5: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F6: This statement is being filed by Goldman Sachs Group, Inc. ("GS Group"), GS&Co, Goldman Sachs Asset Management, L.P. ("GSAM LP"), Broad Street Principal Investments L.L.C. ("BSPI"), which directly holds 96,190 shares of common stock purchased in the IPO and 468,565 shares of common stock converted from 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock, WSLS Offshore Investments, SLP ("WSLS Offshore"), which directly holds 131,283 shares of common stock purchased in the IPO and 639,518 shares of common stock converted from 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock, West Street Life Sciences I, L.P. ("WSLS I"), which directly holds 137,708 shares of common stock purchased in the IPO and 670,812 shares of common stock converted from 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock,... (continued in footnote 7) F7: (continued from footnote 6)...WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore"), which directly holds 36,927 shares of common stock purchased in the IPO and 179,879 shares of common stock converted from 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore"), which directly holds 97,892 shares of common stock purchased in the IPO and 476,858 shares of common stock converted from 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock. GS&Co is a direct subsidiary of GS Group and is the manager of BSPI. WSLS Offshore, WSLS I, WSLS Emp Offshore, and WSLS Emp Onshore are investment vehicles managed by GSAM LP, an indirect subsidiary of GS Group. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2026-08-06 transaction · row 29
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 29 · 2026-08-06 · Conversion · Disposed 4,445,275 · Balance 0 F4: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F5: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F6: This statement is being filed by Goldman Sachs Group, Inc. ("GS Group"), GS&Co, Goldman Sachs Asset Management, L.P. ("GSAM LP"), Broad Street Principal Investments L.L.C. ("BSPI"), which directly holds 96,190 shares of common stock purchased in the IPO and 468,565 shares of common stock converted from 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock, WSLS Offshore Investments, SLP ("WSLS Offshore"), which directly holds 131,283 shares of common stock purchased in the IPO and 639,518 shares of common stock converted from 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock, West Street Life Sciences I, L.P. ("WSLS I"), which directly holds 137,708 shares of common stock purchased in the IPO and 670,812 shares of common stock converted from 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock,... (continued in footnote 7) F7: (continued from footnote 6)...WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore"), which directly holds 36,927 shares of common stock purchased in the IPO and 179,879 shares of common stock converted from 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore"), which directly holds 97,892 shares of common stock purchased in the IPO and 476,858 shares of common stock converted from 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock. GS&Co is a direct subsidiary of GS Group and is the manager of BSPI. WSLS Offshore, WSLS I, WSLS Emp Offshore, and WSLS Emp Onshore are investment vehicles managed by GSAM LP, an indirect subsidiary of GS Group. |
| Equity SwapSEC Table II · derivative / convertible security | IndirectSee Footnotes | 2,872 |
Reported balance
After 2026-08-05 transaction · row 30
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 30 · 2026-08-05 · Purchase · Acquired 2,872 · Balance 2,872 F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. |
| Equity SwapSEC Table II · derivative / convertible security | IndirectSee Footnotes | 31,589 |
Reported balance
After 2026-08-05 transaction · row 31
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 31 · 2026-08-05 · Purchase · Acquired 28,717 · Balance 31,589 F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. |
| Equity SwapSEC Table II · derivative / convertible security | IndirectSee Footnotes | 43,077 |
Reported balance
After 2026-08-05 transaction · row 32
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 32 · 2026-08-05 · Purchase · Acquired 11,488 · Balance 43,077 F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. |
| Equity SwapSEC Table II · derivative / convertible security | IndirectSee Footnotes | 88,665 |
Reported balance
After 2026-08-05 transaction · row 33
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 33 · 2026-08-05 · Purchase · Acquired 45,588 · Balance 88,665 F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. |
| Equity SwapSEC Table II · derivative / convertible security | IndirectSee Footnotes | 100,063 |
Reported balance
After 2026-08-05 transaction · row 34
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 34 · 2026-08-05 · Purchase · Acquired 11,398 · Balance 100,063 F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. |
| Equity SwapSEC Table II · derivative / convertible security | IndirectSee Footnotes | 105,807 |
Reported balance
After 2026-08-05 transaction · row 35
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 35 · 2026-08-05 · Purchase · Acquired 5,744 · Balance 105,807 F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
F2: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer.
F3: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4.
F4: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4.
F5: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO").
F6: This statement is being filed by Goldman Sachs Group, Inc. ("GS Group"), GS&Co, Goldman Sachs Asset Management, L.P. ("GSAM LP"), Broad Street Principal Investments L.L.C. ("BSPI"), which directly holds 96,190 shares of common stock purchased in the IPO and 468,565 shares of common stock converted from 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock, WSLS Offshore Investments, SLP ("WSLS Offshore"), which directly holds 131,283 shares of common stock purchased in the IPO and 639,518 shares of common stock converted from 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock, West Street Life Sciences I, L.P. ("WSLS I"), which directly holds 137,708 shares of common stock purchased in the IPO and 670,812 shares of common stock converted from 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock,... (continued in footnote 7)
F7: (continued from footnote 6)...WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore"), which directly holds 36,927 shares of common stock purchased in the IPO and 179,879 shares of common stock converted from 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore"), which directly holds 97,892 shares of common stock purchased in the IPO and 476,858 shares of common stock converted from 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock. GS&Co is a direct subsidiary of GS Group and is the manager of BSPI. WSLS Offshore, WSLS I, WSLS Emp Offshore, and WSLS Emp Onshore are investment vehicles managed by GSAM LP, an indirect subsidiary of GS Group.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | ConversionSeries C Preferred Stock · Derivative | 4,445,275 | $0.00 | $0.00 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · derivative · entry 29 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 478,598 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F5 · shares: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F5 · derivative.exercise_date: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F5 · derivative.expiration_date: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F4 · derivative.underlying_shares: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F5 · derivative.underlying_shares: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F6 · ownership.nature: This statement is being filed by Goldman Sachs Group, Inc. ("GS Group"), GS&Co, Goldman Sachs Asset Management, L.P. ("GSAM LP"), Broad Street Principal Investments L.L.C. ("BSPI"), which directly holds 96,190 shares of common stock purchased in the IPO and 468,565 shares of common stock converted from 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock, WSLS Offshore Investments, SLP ("WSLS Offshore"), which directly holds 131,283 shares of common stock purchased in the IPO and 639,518 shares of common stock converted from 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock, West Street Life Sciences I, L.P. ("WSLS I"), which directly holds 137,708 shares of common stock purchased in the IPO and 670,812 shares of common stock converted from 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock,... (continued in footnote 7) F7 · ownership.nature: (continued from footnote 6)...WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore"), which directly holds 36,927 shares of common stock purchased in the IPO and 179,879 shares of common stock converted from 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore"), which directly holds 97,892 shares of common stock purchased in the IPO and 476,858 shares of common stock converted from 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock. GS&Co is a direct subsidiary of GS Group and is the manager of BSPI. WSLS Offshore, WSLS I, WSLS Emp Offshore, and WSLS Emp Onshore are investment vehicles managed by GSAM LP, an indirect subsidiary of GS Group. Read SEC document |
| August 06, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | ConversionSeries B Preferred Stock · Derivative | 18,181,830 | $0.00 | $0.00 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · derivative · entry 28 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,957,134 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F5 · shares: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F5 · derivative.exercise_date: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F5 · derivative.expiration_date: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F4 · derivative.underlying_shares: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F5 · derivative.underlying_shares: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F6 · ownership.nature: This statement is being filed by Goldman Sachs Group, Inc. ("GS Group"), GS&Co, Goldman Sachs Asset Management, L.P. ("GSAM LP"), Broad Street Principal Investments L.L.C. ("BSPI"), which directly holds 96,190 shares of common stock purchased in the IPO and 468,565 shares of common stock converted from 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock, WSLS Offshore Investments, SLP ("WSLS Offshore"), which directly holds 131,283 shares of common stock purchased in the IPO and 639,518 shares of common stock converted from 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock, West Street Life Sciences I, L.P. ("WSLS I"), which directly holds 137,708 shares of common stock purchased in the IPO and 670,812 shares of common stock converted from 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock,... (continued in footnote 7) F7 · ownership.nature: (continued from footnote 6)...WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore"), which directly holds 36,927 shares of common stock purchased in the IPO and 179,879 shares of common stock converted from 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore"), which directly holds 97,892 shares of common stock purchased in the IPO and 476,858 shares of common stock converted from 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock. GS&Co is a direct subsidiary of GS Group and is the manager of BSPI. WSLS Offshore, WSLS I, WSLS Emp Offshore, and WSLS Emp Onshore are investment vehicles managed by GSAM LP, an indirect subsidiary of GS Group. Read SEC document |
| August 06, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | PurchaseCommon Stock | 500,000 | $17.00 | $8,500,000.00 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 27 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 3,020,632 F4 · balance_after: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. Read SEC document |
| August 06, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | ConversionCommon Stock | 478,498 | $0.00 | $0.00 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 26 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 2,520,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F5 · shares: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F4 · balance_after: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F6 · ownership.nature: This statement is being filed by Goldman Sachs Group, Inc. ("GS Group"), GS&Co, Goldman Sachs Asset Management, L.P. ("GSAM LP"), Broad Street Principal Investments L.L.C. ("BSPI"), which directly holds 96,190 shares of common stock purchased in the IPO and 468,565 shares of common stock converted from 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock, WSLS Offshore Investments, SLP ("WSLS Offshore"), which directly holds 131,283 shares of common stock purchased in the IPO and 639,518 shares of common stock converted from 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock, West Street Life Sciences I, L.P. ("WSLS I"), which directly holds 137,708 shares of common stock purchased in the IPO and 670,812 shares of common stock converted from 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock,... (continued in footnote 7) F7 · ownership.nature: (continued from footnote 6)...WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore"), which directly holds 36,927 shares of common stock purchased in the IPO and 179,879 shares of common stock converted from 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore"), which directly holds 97,892 shares of common stock purchased in the IPO and 476,858 shares of common stock converted from 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock. GS&Co is a direct subsidiary of GS Group and is the manager of BSPI. WSLS Offshore, WSLS I, WSLS Emp Offshore, and WSLS Emp Onshore are investment vehicles managed by GSAM LP, an indirect subsidiary of GS Group. Read SEC document |
| August 06, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | ConversionCommon Stock | 1,957,134 | $0.00 | $0.00 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 25 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 2,042,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F5 · shares: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F4 · balance_after: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F6 · ownership.nature: This statement is being filed by Goldman Sachs Group, Inc. ("GS Group"), GS&Co, Goldman Sachs Asset Management, L.P. ("GSAM LP"), Broad Street Principal Investments L.L.C. ("BSPI"), which directly holds 96,190 shares of common stock purchased in the IPO and 468,565 shares of common stock converted from 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock, WSLS Offshore Investments, SLP ("WSLS Offshore"), which directly holds 131,283 shares of common stock purchased in the IPO and 639,518 shares of common stock converted from 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock, West Street Life Sciences I, L.P. ("WSLS I"), which directly holds 137,708 shares of common stock purchased in the IPO and 670,812 shares of common stock converted from 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock,... (continued in footnote 7) F7 · ownership.nature: (continued from footnote 6)...WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore"), which directly holds 36,927 shares of common stock purchased in the IPO and 179,879 shares of common stock converted from 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore"), which directly holds 97,892 shares of common stock purchased in the IPO and 476,858 shares of common stock converted from 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock. GS&Co is a direct subsidiary of GS Group and is the manager of BSPI. WSLS Offshore, WSLS I, WSLS Emp Offshore, and WSLS Emp Onshore are investment vehicles managed by GSAM LP, an indirect subsidiary of GS Group. Read SEC document |
| August 06, 2026 Filed Aug 28, 2026 21:38 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | ConversionSeries C Preferred Stock · Derivative | 4,445,275 | $0.00 | $0.00 |
DisclosureSEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · derivative · entry 29 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 478,598 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F5 · shares: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F5 · derivative.exercise_date: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F5 · derivative.expiration_date: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F4 · derivative.underlying_shares: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F5 · derivative.underlying_shares: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F6 · ownership.nature: This statement is being filed by Goldman Sachs Group, Inc. ("GS Group"), GS&Co, Goldman Sachs Asset Management, L.P. ("GSAM LP"), Broad Street Principal Investments L.L.C. ("BSPI"), which directly holds 96,190 shares of common stock purchased in the IPO and 468,565 shares of common stock converted from 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock, WSLS Offshore Investments, SLP ("WSLS Offshore"), which directly holds 131,283 shares of common stock purchased in the IPO and 639,518 shares of common stock converted from 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock, West Street Life Sciences I, L.P. ("WSLS I"), which directly holds 137,708 shares of common stock purchased in the IPO and 670,812 shares of common stock converted from 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock,... (continued in footnote 7) F7 · ownership.nature: (continued from footnote 6)...WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore"), which directly holds 36,927 shares of common stock purchased in the IPO and 179,879 shares of common stock converted from 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore"), which directly holds 97,892 shares of common stock purchased in the IPO and 476,858 shares of common stock converted from 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock. GS&Co is a direct subsidiary of GS Group and is the manager of BSPI. WSLS Offshore, WSLS I, WSLS Emp Offshore, and WSLS Emp Onshore are investment vehicles managed by GSAM LP, an indirect subsidiary of GS Group. Read SEC document |
| August 06, 2026 Filed Aug 28, 2026 21:38 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | ConversionSeries B Preferred Stock · Derivative | 18,181,830 | $0.00 | $0.00 |
DisclosureSEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · derivative · entry 28 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,957,134 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F5 · shares: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F5 · derivative.exercise_date: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F5 · derivative.expiration_date: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F4 · derivative.underlying_shares: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F5 · derivative.underlying_shares: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F6 · ownership.nature: This statement is being filed by Goldman Sachs Group, Inc. ("GS Group"), GS&Co, Goldman Sachs Asset Management, L.P. ("GSAM LP"), Broad Street Principal Investments L.L.C. ("BSPI"), which directly holds 96,190 shares of common stock purchased in the IPO and 468,565 shares of common stock converted from 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock, WSLS Offshore Investments, SLP ("WSLS Offshore"), which directly holds 131,283 shares of common stock purchased in the IPO and 639,518 shares of common stock converted from 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock, West Street Life Sciences I, L.P. ("WSLS I"), which directly holds 137,708 shares of common stock purchased in the IPO and 670,812 shares of common stock converted from 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock,... (continued in footnote 7) F7 · ownership.nature: (continued from footnote 6)...WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore"), which directly holds 36,927 shares of common stock purchased in the IPO and 179,879 shares of common stock converted from 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore"), which directly holds 97,892 shares of common stock purchased in the IPO and 476,858 shares of common stock converted from 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock. GS&Co is a direct subsidiary of GS Group and is the manager of BSPI. WSLS Offshore, WSLS I, WSLS Emp Offshore, and WSLS Emp Onshore are investment vehicles managed by GSAM LP, an indirect subsidiary of GS Group. Read SEC document |
| August 06, 2026 Filed Aug 28, 2026 21:38 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | PurchaseCommon Stock | 500,000 | $17.00 | $8,500,000.00 |
DisclosureSEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · nonDerivative · entry 27 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 3,020,632 F4 · balance_after: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. Read SEC document |
| August 06, 2026 Filed Aug 28, 2026 21:38 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | ConversionCommon Stock | 478,498 | $0.00 | $0.00 |
DisclosureSEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · nonDerivative · entry 26 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 2,520,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F5 · shares: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F4 · balance_after: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F6 · ownership.nature: This statement is being filed by Goldman Sachs Group, Inc. ("GS Group"), GS&Co, Goldman Sachs Asset Management, L.P. ("GSAM LP"), Broad Street Principal Investments L.L.C. ("BSPI"), which directly holds 96,190 shares of common stock purchased in the IPO and 468,565 shares of common stock converted from 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock, WSLS Offshore Investments, SLP ("WSLS Offshore"), which directly holds 131,283 shares of common stock purchased in the IPO and 639,518 shares of common stock converted from 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock, West Street Life Sciences I, L.P. ("WSLS I"), which directly holds 137,708 shares of common stock purchased in the IPO and 670,812 shares of common stock converted from 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock,... (continued in footnote 7) F7 · ownership.nature: (continued from footnote 6)...WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore"), which directly holds 36,927 shares of common stock purchased in the IPO and 179,879 shares of common stock converted from 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore"), which directly holds 97,892 shares of common stock purchased in the IPO and 476,858 shares of common stock converted from 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock. GS&Co is a direct subsidiary of GS Group and is the manager of BSPI. WSLS Offshore, WSLS I, WSLS Emp Offshore, and WSLS Emp Onshore are investment vehicles managed by GSAM LP, an indirect subsidiary of GS Group. Read SEC document |
| August 06, 2026 Filed Aug 28, 2026 21:38 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | ConversionCommon Stock | 1,957,134 | $0.00 | $0.00 |
DisclosureSEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · nonDerivative · entry 25 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 2,042,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F5 · shares: All shares of the Issuer's redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, adjusted for a 1-for-9.29 reverse stock split effected by the Issuer on July 29, 2026, upon the completion of the Issuer's initial public offering (the "IPO"). F4 · balance_after: The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4. F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F6 · ownership.nature: This statement is being filed by Goldman Sachs Group, Inc. ("GS Group"), GS&Co, Goldman Sachs Asset Management, L.P. ("GSAM LP"), Broad Street Principal Investments L.L.C. ("BSPI"), which directly holds 96,190 shares of common stock purchased in the IPO and 468,565 shares of common stock converted from 3,497,806 shares of Series B Preferred Stock and 855,179 shares of Series C Preferred Stock, WSLS Offshore Investments, SLP ("WSLS Offshore"), which directly holds 131,283 shares of common stock purchased in the IPO and 639,518 shares of common stock converted from 4,773,948 shares of Series B Preferred Stock and 1,167,182 shares of Series C Preferred Stock, West Street Life Sciences I, L.P. ("WSLS I"), which directly holds 137,708 shares of common stock purchased in the IPO and 670,812 shares of common stock converted from 5,007,564 shares of Series B Preferred Stock and 1,224,299 shares of Series C Preferred Stock,... (continued in footnote 7) F7 · ownership.nature: (continued from footnote 6)...WSLS Emp Offshore Investments, L.P. ("WSLS Emp Offshore"), which directly holds 36,927 shares of common stock purchased in the IPO and 179,879 shares of common stock converted from 1,342,794 shares of Series B Preferred Stock and 328,300 shares of Series C Preferred Stock, and WSLS Emp Onshore Investments, L.P. ("WSLS Emp Onshore"), which directly holds 97,892 shares of common stock purchased in the IPO and 476,858 shares of common stock converted from 3,559,718 shares of Series B Preferred Stock and 870,315 shares of Series C Preferred Stock. GS&Co is a direct subsidiary of GS Group and is the manager of BSPI. WSLS Offshore, WSLS I, WSLS Emp Offshore, and WSLS Emp Onshore are investment vehicles managed by GSAM LP, an indirect subsidiary of GS Group. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 76,418 | $21.04 | $1,607,834.72 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 24 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 6,763 | $21.61 | $146,148.43 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 23 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 55,611 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 100 | $21.99 | $2,199.00 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 22 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 62,374 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 1,163 | $22.19 | $25,806.97 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 21 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 62,474 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 700 | $22.07 | $15,449.00 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 20 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 63,637 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 200 | $22.05 | $4,410.00 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 19 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 64,337 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 443 | $21.78 | $9,648.54 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 18 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 64,537 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 300 | $20.84 | $6,252.00 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 17 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 64,980 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 1,040 | $22.05 | $22,932.00 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 16 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 65,280 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 1,180 | $21.84 | $25,771.20 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 15 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 66,320 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 400 | $22.02 | $8,808.00 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 14 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 67,500 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 6,970 | $22.03 | $153,549.10 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 13 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 67,900 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 672 | $22.02 | $14,797.44 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 12 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 74,870 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 753 | $21.97 | $16,543.41 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 11 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 75,542 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 100 | $22.11 | $2,211.00 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 10 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 76,295 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 480 | $21.55 | $10,344.00 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 9 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 76,395 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 200 | $22.10 | $4,420.00 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 8 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 76,875 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 3,402 | $22.02 | $74,912.04 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 7 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 77,075 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 1,556 | $22.06 | $34,325.36 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 6 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 80,477 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 200 | $22.05 | $4,410.00 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 5 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 82,033 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 1,332 | $22.03 | $29,343.96 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 4 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 82,233 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 447 | $21.87 | $9,775.89 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 3 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 83,565 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 988 | $22.03 | $21,765.64 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 2 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 84,012 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares and sales of a total of 105,807 shares. Read SEC document |
| August 05, 2026 Filed Aug 14, 2026 01:51 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | PurchaseCommon Stock | 85,000 | $21.00 | $1,785,000.00 |
DisclosureSEC source: 0000886982-26-000495 · wk-form4_1786672305.xml · nonDerivative · entry 1 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 85,000 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. Read SEC document |
| August 05, 2026 Filed Aug 28, 2026 21:38 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | PurchaseEquity Swap · Derivative | 5,744 | $21.22 | $121,887.68 |
DisclosureSEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · derivative · entry 35 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 105,807 Underlying: Common Stock · 5,744 shares Expires not disclosed F3 · derivative.exercise_price: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F3 · derivative.exercise_date: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F3 · derivative.expiration_date: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. Read SEC document |
| August 05, 2026 Filed Aug 28, 2026 21:38 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | PurchaseEquity Swap · Derivative | 11,398 | $21.27 | $242,435.46 |
DisclosureSEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · derivative · entry 34 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 100,063 Underlying: Common Stock · 11,398 shares Expires not disclosed F3 · derivative.exercise_price: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F3 · derivative.exercise_date: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F3 · derivative.expiration_date: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. Read SEC document |
| August 05, 2026 Filed Aug 28, 2026 21:38 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | PurchaseEquity Swap · Derivative | 45,588 | $21.27 | $969,656.76 |
DisclosureSEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · derivative · entry 33 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 88,665 Underlying: Common Stock · 45,588 shares Expires not disclosed F3 · derivative.exercise_price: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F3 · derivative.exercise_date: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F3 · derivative.expiration_date: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. Read SEC document |
| August 05, 2026 Filed Aug 28, 2026 21:38 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | PurchaseEquity Swap · Derivative | 11,488 | $21.22 | $243,775.36 |
DisclosureSEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · derivative · entry 32 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 43,077 Underlying: Common Stock · 11,488 shares Expires not disclosed F3 · derivative.exercise_price: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F3 · derivative.exercise_date: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F3 · derivative.expiration_date: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. Read SEC document |
| August 05, 2026 Filed Aug 28, 2026 21:38 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | PurchaseEquity Swap · Derivative | 28,717 | $21.22 | $609,374.74 |
DisclosureSEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · derivative · entry 31 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 31,589 Underlying: Common Stock · 28,717 shares Expires not disclosed F3 · derivative.exercise_price: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F3 · derivative.exercise_date: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F3 · derivative.expiration_date: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. Read SEC document |
| August 05, 2026 Filed Aug 28, 2026 21:38 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | PurchaseEquity Swap · Derivative | 2,872 | $21.22 | $60,943.84 |
DisclosureSEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · derivative · entry 30 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 2,872 Underlying: Common Stock · 2,872 shares Expires not disclosed F3 · derivative.exercise_price: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F3 · derivative.exercise_date: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F3 · derivative.expiration_date: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. Read SEC document |
| August 05, 2026 Filed Aug 28, 2026 21:38 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 76,418 | $21.04 | $1,607,834.72 |
DisclosureSEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · nonDerivative · entry 24 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. Read SEC document |
| August 05, 2026 Filed Aug 28, 2026 21:38 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 6,763 | $21.61 | $146,148.43 |
DisclosureSEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · nonDerivative · entry 23 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 55,611 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. Read SEC document |
| August 05, 2026 Filed Aug 28, 2026 21:38 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 100 | $21.99 | $2,199.00 |
DisclosureSEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · nonDerivative · entry 22 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 62,374 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. Read SEC document |
| August 05, 2026 Filed Aug 28, 2026 21:38 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 1,163 | $22.19 | $25,806.97 |
DisclosureSEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · nonDerivative · entry 21 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 62,474 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. Read SEC document |
| August 05, 2026 Filed Aug 28, 2026 21:38 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 700 | $22.07 | $15,449.00 |
DisclosureSEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · nonDerivative · entry 20 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 63,637 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. Read SEC document |
| August 05, 2026 Filed Aug 28, 2026 21:38 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 200 | $22.05 | $4,410.00 |
DisclosureSEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · nonDerivative · entry 19 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 64,337 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. Read SEC document |
| August 05, 2026 Filed Aug 28, 2026 21:38 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 443 | $21.78 | $9,648.54 |
DisclosureSEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · nonDerivative · entry 18 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 64,537 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. Read SEC document |
| August 05, 2026 Filed Aug 28, 2026 21:38 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 300 | $20.84 | $6,252.00 |
DisclosureSEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · nonDerivative · entry 17 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 64,980 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. Read SEC document |
| August 05, 2026 Filed Aug 28, 2026 21:38 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 1,040 | $22.05 | $22,932.00 |
DisclosureSEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · nonDerivative · entry 16 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 65,280 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. Read SEC document |
| August 05, 2026 Filed Aug 28, 2026 21:38 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | SaleCommon Stock | 1,180 | $21.84 | $25,771.20 |
DisclosureSEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · nonDerivative · entry 15 GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 66,320 F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. F2 · ownership.nature: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer. F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.